(Q44841100)

English

A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes

scientific article published on 6 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes (English)

1 reference

Europe PubMed Central

6 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

E Leifke

1

1 reference

Europe PubMed Central

6 December 2017

H Naik

2

1 reference

Europe PubMed Central

6 December 2017

J Wu

3

1 reference

Europe PubMed Central

6 December 2017

P Viswanathan

4

1 reference

Europe PubMed Central

6 December 2017

D Demanno

5

1 reference

Europe PubMed Central

6 December 2017

M Kipnes

6

1 reference

Europe PubMed Central

6 December 2017

M Vakilynejad

7

1 reference

Europe PubMed Central

6 December 2017

language of work or name

0 references

publication date

6 June 2012

1 reference

Europe PubMed Central

6 December 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

6 December 2017

92

1 reference

Europe PubMed Central

6 December 2017

1

1 reference

Europe PubMed Central

6 December 2017

29-39

1 reference

Europe PubMed Central

6 December 2017

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Common variants at the GCK, GCKR, G6PC2-ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Diabetic nephropathy: important pathophysiologic mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

21 January 2018

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating hyperglycemia in type 2 diabetes: new goals and strategies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.43

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2012.43

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44841100&oldid=2143944999"